Lantheus (LNTH) 10-Q 1 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	LNTH
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Central Index Key	1,521,036
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		35,724,793

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenues	$ 73,063	$ 74,123	$ 227,503	$ 222,260
Cost of goods sold	39,382	40,418	124,370	120,119
Gross profit	33,681	33,705	103,133	102,141
Operating expenses
Sales and marketing	8,706	8,633	27,856	26,934
General and administrative	10,091	9,206	28,842	33,773
Research and development	2,849	2,458	8,493	11,292
Total operating expenses	21,646	20,297	65,191	71,999
Gain on sales of assets	560		6,505
Operating income	12,595	13,408	44,447	30,142
Interest expense, net	(6,786)	(7,100)	(20,782)	(31,599)
Debt retirement costs	(1,415)		(1,415)
Loss on extinguishment of debt				(15,528)
Other (expense) income, net	(154)	(183)	300	234
Income (loss) before income taxes	4,240	6,125	22,550	(16,751)
Provision for income taxes	20	739	657	1,911
Net income (loss)	$ 4,220	$ 5,386	$ 21,893	$ (18,662)
Net income (loss) per weighted-average common share outstanding:
Basic	$ 0.14	$ 0.18	$ 0.71	$ (0.83)
Diluted	$ 0.13	$ 0.18	$ 0.71	$ (0.83)
Weighted-average common shares outstanding:
Basic	31,220,877	30,359,516	30,657,623	22,443,257
Diluted	32,402,297	30,761,771	31,049,351	22,443,257

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 4,220	$ 5,386	$ 21,893	$ (18,662)
Other comprehensive income (loss):
Reclassification adjustment for gains on sales of assets included in net income (loss)	435		435
Foreign currency translation	234	(443)	490	(817)
Total other comprehensive income (loss)	669	(443)	925	(817)
Comprehensive income (loss)	$ 4,889	$ 4,943	$ 22,818	$ (19,479)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 53,195	$ 28,596
Accounts receivable, net of allowance of $907 and $881	34,844	37,293
Inventory	16,057	15,622
Other current assets	6,369	3,851
Assets held for sale		4,644
Total current assets	110,465	90,006
Property, plant & equipment, net	84,980	86,517
Capitalized software development costs, net	7,676	9,137
Intangibles, net	16,406	20,496
Goodwill	15,714	15,714
Other long-term assets	19,728	20,509
Total assets	254,969	242,379
Current liabilities:
Current portion of long-term debt	3,650	3,650
Accounts payable	13,617	11,657
Accrued expenses and other current liabilities	21,850	18,502
Liabilities held for sale		1,715
Total current liabilities	39,117	35,524
Asset retirement obligation	8,710	8,145
Long-term debt, net	294,582	349,858
Other long-term liabilities	33,716	34,141
Total liabilities	376,125	427,668
Commitments and contingencies (See Note 14)
Stockholders' deficit:
Preferred stock ($0.01 par value, 25,000,000 shares authorized; no shares issued and outstanding)
Common stock ($0.01 par value, 250,000,000 shares authorized; 35,714,792 and 30,364,501 shares issued and outstanding, respectively)	357	303
Additional paid-in capital	216,814	175,553
Accumulated deficit	(337,267)	(359,160)
Accumulated other comprehensive loss	(1,060)	(1,985)
Total stockholders' deficit	(121,156)	(185,289)
Total liabilities and stockholders' deficit	$ 254,969	$ 242,379

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 907	$ 881
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	35,714,792	30,364,501
Common stock, shares outstanding	35,714,792	30,364,501

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Deficit - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands	Total	Follow-on Offering [Member]	Common Stock [Member]	Common Stock [Member]Follow-on Offering [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Follow-on Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2015	$ (185,289)		$ 303		$ 175,553		$ (359,160)	$ (1,985)
Balance, (in shares) at Dec. 31, 2015			30,364,501
Other comprehensive income	925							925
Vesting of restricted stock awards			$ 2		(2)
Vesting of restricted stock awards,shares			197,392
Issuance of common stock		$ 39,937		$ 52		$ 39,885
Issuance of common stock,shares				5,200,000
Shares withheld to cover taxes	(552)				(552)
Shares withheld to cover taxes,shares			(58,077)
Stock option exercises	61				61
Stock option exercises,shares			10,976
Stock-based compensation	1,869				1,869
Net income	21,893						21,893
Balance at Sep. 30, 2016	$ (121,156)		$ 357		$ 216,814		$ (337,267)	$ (1,060)
Balance, (in shares) at Sep. 30, 2016			35,714,792

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Stockholders' Deficit (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Follow-on Offering [Member]
Follow-on offering, issuance costs	$ 1,663

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net income (loss)	$ 21,893	$ (18,662)
Adjustments to reconcile net income (loss) to cash flows from operating activities:
Depreciation and amortization	13,200	16,648
Debt retirement costs	1,415
Provision for excess and obsolete inventory	982	1,073
Stock-based compensation expense	1,869	1,524
Loss on extinguishment of debt		15,528
Gain on sales of assets	(6,505)
Other	(445)	2,513
Changes in operating assets and liabilities:
Accounts receivable	1,071	790
Inventory	(1,658)	(2,441)
Other current assets	(1,032)	(1,075)
Accounts payable	2,684	(2,765)
Accrued expenses and other liabilities	2,497	(3,997)
Cash provided by operating activities	36,861	9,136
Investing Activities
Proceeds from sales of assets	10,541
Capital expenditures	(4,976)	(8,419)
Redemption of certificate of deposit-restricted	74
Cash provided by (used in) investing activities	5,639	(8,419)
Financing Activities
Proceeds from issuance of common stock in public offering	41,600	73,539
Payments for offering costs	(1,266)	(6,821)
Proceeds from issuance of long-term debt		360,438
Principal payments on long-term debt	(57,790)	(969)
Principal payments on senior notes		(400,000)
Payment for call premium on senior notes		(9,752)
Repayments of amounts borrowed under revolving line of credit		(8,000)
Payments of minimum statutory tax withholdings on net share settlements of equity awards	(552)	(97)
Proceeds from stock option exercises	61
Deferred financing costs	(11)	(6,297)
Cash (used in) provided by financing activities	(17,958)	2,041
Effect of foreign exchange rates on cash and cash equivalents	57	(575)
Increase in cash and cash equivalents	24,599	2,183
Cash and cash equivalents, beginning of period	28,596	19,739
Cash and cash equivalents, end of period	$ 53,195	$ 21,922

Business Overview

Business Overview	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	1. Business Overview Description of Business Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation. The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers, and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations. The Company sells its products globally and has operations in the United States, Puerto Rico and Canada and third-party distribution relationships in Europe, Australia, Asia Pacific and Latin America. The Company’s portfolio of nine commercial products is diversified across a range of imaging procedures. The Company’s imaging agents and products include the following: • DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle. • TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents. • Xenon Xe 133 Gas (“Xenon”) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow. • Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography (“SPECT”), technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke. • Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name Sestamibi, used with SPECT technology in myocardial perfusion imaging (“MPI”), procedures that assess blood flow distribution to the heart. In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through third party commercial radiopharmacies. The Company’s International operations consist of sales directly to end users through its wholly owned radiopharmacy in Puerto Rico and sales through the Company’s distributors in Canada, Europe, Australia, Asia Pacific and Latin America. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 2, 2016 and updated, as necessary, in this quarterly report. There were no other changes to the Company’s accounting policies since December 31, 2015. In the opinion of management, the accompanying unaudited condensed consolidated financial statements of Lantheus Holdings, Inc. include all normal and recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of September 30, 2016 and December 31, 2015, results of operations and comprehensive earnings for the three and nine months ended September 30, 2016 and 2015, and cash flows for the nine months ended September 30, 2016 and 2015. The results of operations for the nine months ended September 30, 2016 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Manufacturing and Customer Concentrations, Liquidity and Management’s Plans The Company currently relies on Jubilant HollisterStier (“JHS”) as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company recently completed its technology transfer activities at JHS and received Food and Drug Administration (“FDA”) approval for its Cardiolite product supply. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY. Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives. The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy. Borrowing capacity under the Company’s $50.0 million revolving credit facility (the “Revolving Facility”), is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves (the “Borrowing Base”). If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of September 30, 2016, the aggregate Borrowing Base was approximately $40.4 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $31.5 million. The Company’s senior secured term loan facility (the “Term Facility”), contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity. Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions. Recent Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain cash Receipts and Cash Payments In March 2016, the FASB, issued ASU 2016-09, Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606 Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	2. Fair Value of Financial Instruments The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability. September 30, 2016 (in thousands) Total fair Quoted prices Significant other Significant Money market (1) $ 3,050 $ 3,050 $ — $ — Total $ 3,050 $ 3,050 $ — $ — December 31, 2015 (in thousands) Total fair Quoted prices Significant other Significant Money market (1) $ 1,586 $ 1,586 $ — $ — Certificates of deposit—restricted 74 — 74 — Total $ 1,660 $ 1,586 $ 74 $ — (1) Money market funds are included in cash and cash equivalents in the accompanying consolidated balance sheets; valued at quoted market prices in active markets. The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company’s Term Facility at both September 30, 2016 and December 31, 2015, approximated the carrying value because the interest rate is subject to change with market interest rates.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	3. Income Taxes The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company’s tax provision was $20,000 and $0.7 million for the three and nine months ended September 30, 2016, respectively, and $0.7 million and $1.9 million for the three and nine months ended September 30, 2015, respectively. During the first quarter of 2016, the Company early adopted ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes

Sales of Certain International

Sales of Certain International Segment Assets	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Sales of Certain International Segment Assets	4. Sales of Certain International Segment Assets Sale of Certain Canadian Assets During the fourth quarter of 2015, the Company committed to a plan to sell certain assets and liabilities associated with the Company’s international business in Canada. This event qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2015. The transaction was finalized in the first quarter of 2016. Effective January 7, 2016, the Canadian subsidiary of the Company entered into an asset purchase agreement (“Canadian Purchase Agreement”) pursuant to which it would sell substantially all of the assets of its Canadian radiopharmacy businesses and Gludef manufacturing and distribution business to one of its existing Canadian radiopharmacy customers. The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million, which was settled in the third quarter of 2016. The Canadian Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Canadian Purchase Agreement. As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with certain of the Company’s products on commercial terms and under which the buyer has agreed to certain product purchase commitments. The Company did not believe the sale of certain net assets in the international segment constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s financial statements and was classified as assets and liabilities held for sale as of December 31, 2015. The following table summarizes the major classes of assets and liabilities sold as of January 12, 2016 (date of the sale) and held for sale as of December 31, 2015: (in thousands) January 12, December 31, Current Assets: Accounts receivable, net $ 2,620 $ 2,512 Inventory 730 806 Other current assets 15 26 Total current assets 3,365 3,344 Non-Current Assets: Property, plant & equipment, net 760 791 Intangibles, net 462 480 Other long-term assets 28 29 Total assets held for sale $ 4,615 $ 4,644 Current Liabilities: Accounts payable $ 435 $ 430 Accrued expense and other liabilities 858 1,285 Total liabilities held for sale $ 1,293 $ 1,715 The sale resulted in a pre-tax book gain of $5.9 million, which was recorded within gain on sales of assets in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2016. Sale of Australian Radiopharmacy Servicing Subsidiary Effective August 11, 2016, the Company entered into a share purchase agreement (“Australian Purchase Agreement”) pursuant to which it sold all of the stock of its Australian radiopharmacy servicing subsidiary to one of its existing radiopharmacy customers. The sale price was AUD$2.0 million (approximately $1.5 million U.S. Dollars) in cash and also included a working capital adjustment of approximately AUD$2.0 million (approximately $1.5 million U.S. Dollars) for total proceeds of approximately AUD$4.0 million (approximately $3.0 million U.S. Dollars) from the sale. As a result of this sale, the Company disposed of net assets of $2.2 million primarily comprised of working capital accounts of $2.0 million. The sale resulted in a pre-tax book gain of $0.6 million, which was recorded within gain on sales of assets in the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2016. As a result of the sale of the Australian subsidiary, the Company reclassified $0.5 million from other comprehensive income to gain on sale of assets in the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2016. The Australian Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Australian Purchase Agreement. As part of the transaction, the Company and the buyer also entered into a long-term supply and distribution contract under which the Company will supply the buyer and its subsidiaries with the Company’s products on commercial terms and under which the buyer has agreed to certain product purchase commitments. The Company did not believe the sale of certain net assets in the international segment constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory was comprised of the following as of the end of each period: (in thousands) September 30, December 31, Raw materials $ 6,951 $ 7,506 Work in process 4,597 2,407 Finished goods 4,509 5,709 Total Inventory $ 16,057 $ 15,622 As of September 30, 2016 and December 31, 2015, the Company had $1.2 million of inventory classified within other long-term assets, which represent raw materials that are not expected to be used by the Company during the next 12 months.

Property, Plant & Equipment, ne

Property, Plant & Equipment, net	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant & Equipment, net	6. Property, Plant & Equipment, net Property, plant & equipment consisted of the following: (in thousands) September 30, December 31, Land $ 14,950 $ 14,950 Buildings 70,294 68,941 Machinery, equipment and fixtures 66,229 60,787 Sub-total 151,473 144,678 Less: Accumulated depreciation (72,174 ) (67,260 ) Property, plant & equipment in service 79,299 77,418 Construction in progress 5,681 9,099 Property, plant & equipment, net $ 84,980 $ 86,517 For the three and nine months ended September 30, 2016, the Company recorded depreciation expense of $2.1 million and $6.2 million, respectively, and $1.9 million and $9.6 million for the three and nine months ended September 30, 2015. Property, plant & equipment dedicated to research and development (“R&D”), activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of $3.9 million as of September 30, 2016. The Company believes these assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these assets, then they could be subject to impairment in the future.

Asset Retirement Obligations

Asset Retirement Obligations	9 Months Ended
	Sep. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations	7. Asset Retirement Obligations The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive production facilities as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites. The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of September 30, 2016, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.1 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset’s useful life. The following is a reconciliation of the Company’s asset retirement obligations for the nine months ended September 30, 2016: (in thousands) Balance at December 31, 2015 $ 8,145 Net increase due to changes in estimated future cash flows 322 Accretion expense 698 Balance at September 30, 2016 9,165 Less: Amounts included in accrued expenses and other liabilities (455 ) Asset retirement obligation, long-term $ 8,710

Intangibles, net

Intangibles, net	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, net	8. Intangibles, net Intangibles, net consisted of the following: September 30, 2016 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ (8,298 ) $ 5,242 Straight-line Customer relationships 99,018 (89,115 ) 9,903 Accelerated Patents 42,780 (41,519 ) 1,261 Straight-line Total $ 155,338 $ (138,932 ) $ 16,406 December 31, 2015 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ (6,934 ) $ 6,606 Straight-line Customer relationships 100,737 (88,564 ) 12,173 Accelerated Patents 42,780 (41,063 ) 1,717 Straight-line Total $ 157,057 $ (136,561 ) $ 20,496 For the three and nine months ended September 30, 2016, the Company recorded amortization expense for its intangible assets of $1.3 million and $3.9 million, respectively, as compared to $1.5 million and $4.5 million for the prior year comparative periods. Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2016 $ 1,277 2017 3,341 2018 2,647 2019 1,804 2020 1,569 2021 and thereafter 5,768 $ 16,406

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Accrued Expenses and Other Current Liabilities	9. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: (in thousands) September 30, December 31, Compensation and benefits $ 12,216 $ 10,525 Freight, distribution and operations 3,435 2,962 Accrued rebates, discounts and chargebacks 2,593 2,085 Accrued professional fees 1,636 1,493 Marketing expense 600 490 Research and development services 229 360 Other 1,141 587 Total accrued expenses and other current liabilities $ 21,850 $ 18,502

Financing Arrangements

Financing Arrangements	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Financing Arrangements	10. Financing Arrangements Term Facility On June 30, 2015, the Company entered into a $365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of $4.6 million. The Company has a right to request an increase of the Term Facility in an aggregate amount up to $37.5 million plus additional amounts subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the initial public offering (“IPO”), and cash on hand, were used to refinance in full the aggregate principal amount of the $400.0 million 9.750% Senior Notes (“the Notes”) and pay related premiums, interest and expenses. The term loans under the Term Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each Interest Period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter. At September 30, 2016, the Company’s interest rate under the Term Facility was 7.00%. The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty. The Company is required to make quarterly payments, which began on September 30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility. The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June 30, 2022. The Term Facility will require the Company to prepay outstanding term loans, subject to certain exceptions, with: • 100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months; • 100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility; and • 50% (with two leverage-based stepdowns) of the Company’s excess cash flow. The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility as directed by LMI, or in the absence of direction, in direct order of maturity. The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate. In September 2016, the Company made a voluntary prepayment of $55.0 million on the Term Facility with the net proceeds of $39.9 million received from a follow-on underwritten primary offering of the Company’s common stock and approximately $15.1 million from available cash on hand. This voluntary prepayment represented a partial extinguishment of the Term Facility. Accordingly, the Company recognized debt retirement costs totaling $1.4 million in the accompanying condensed consolidated statement of operations representing the pro-rata portion of the unamortized debt issuance costs and original issue discount at the date of the payment. The Company’s maturities of principal obligations under the Term Facility are as follows as of September 30, 2016: (in thousands) Remainder of 2016 $ 913 2017 3,650 2018 3,650 2019 3,650 2020 3,650 2021 and thereafter 289,925 Total debt 305,438 Less: Unamortized debt discount (3,139 ) Less: Unamortized debt issuance costs (4,067 ) Total 298,232 Less: Current portion of long-term debt (3,650 ) Total Long-term debt, net $ 294,582 Term Facility Covenants The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below: Term Facility Financial Covenants Period Total Net Leverage Ratio Q2 2016 to Q4 2016 6.00 to 1.00 Q1 2017 to Q2 2017 5.50 to 1.00 Thereafter 5.00 to 1.00 The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates. Revolving Line of Credit At September 30, 2016, the Company had a Revolving Facility with an aggregate principal amount not to exceed $50.0 million. The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020. As of September 30, 2016, the Company has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017. It automatically renewed for a one year period and will continue to automatically renew for a one year period at each anniversary date, unless the Company elects not to renew in writing within 60 days prior to such expiration. The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of September 30, 2016, the aggregate Borrowing Base was approximately $40.4 million, which was reduced by an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $31.5 million. Revolving Line of Credit Covenants The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require the Company to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation As of June 24, 2015, the Company adopted the 2015 Equity Incentive Plan, which was further amended on April 26, 2016 (the “2015 Plan”). The Company’s employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units and dividend equivalent rights (“DERs”) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DERs are treated as separate awards. The number of shares authorized for issuance under the 2015 Plan increased to 4,555,277 on April 26, 2016. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options. The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Nine Months Ended (in thousands) 2016 2015 2016 2015 Cost of goods sold $ 120 $ 51 $ 259 $ 102 General and administrative 487 417 1,065 1,095 Sales and marketing 123 71 251 186 Research and development 147 52 294 141 Total stock-based compensation expense $ 877 $ 591 $ 1,869 $ 1,524

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	12. Net Income (Loss) Per Common Share Basic income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted-average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. Three Months Ended Nine Months Ended (in thousands, except share and per share amounts) 2016 2015 2016 2015 Net income (loss) $ 4,220 $ 5,386 $ 21,893 $ (18,662 ) Basic weighted-average common shares outstanding 31,220,877 30,359,516 30,657,623 22,443,257 Effect of dilutive restricted stock awards 1,084,571 289,911 391,728 — Effect of dilutive stock options 96,849 112,344 — — Diluted weighted-average common shares outstanding 32,402,297 30,761,771 31,049,351 22,443,257 Basic income (loss) per weighted-average common share outstanding $ 0.14 $ 0.18 $ 0.71 $ (0.83 ) Diluted income (loss) per weighted-average common share outstanding $ 0.13 $ 0.18 $ 0.71 $ (0.83 ) The stock options and nonvested restricted stock excluded from weighted-average common shares because of their antidilutive effect for the three and nine months ended September 30, 2016 and 2015 include: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Stock Options 428,121 646,329 1,068,156 1,321,771 Restricted Stock 19,662 6,993 804,624 1,092,361

Other (Expense) Income, net

Other (Expense) Income, net	9 Months Ended
	Sep. 30, 2016
Other Income and Expenses [Abstract]
Other (Expense) Income, net	13. Other (Expense) Income, net Three Months Ended Nine Months Ended (in thousands) 2016 2015 2016 2015 Foreign currency losses $ (349 ) $ (628 ) $ (330 ) $ (989 ) Tax indemnification income 196 439 632 1,216 Other (expense) income (1 ) 6 (2 ) 7 Total Other (expense) income, net $ (154 ) $ (183 ) $ 300 $ 234

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	14. Legal Proceedings and Contingencies From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of September 30, 2016, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Avista, the Company’s largest shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of $6.5 million, which was included in general and administrative expenses in the condensed consolidated statement of operations during the quarter ended June 30, 2015. During both the three months ended September 30, 2016 and 2015, the Company did not incur any costs associated with this agreement. During the nine months ended September 30, 2016, the Company did not incur any costs associated with this agreement as compared to $7.0 million for the prior year comparative period. At September 30, 2016 and December 31, 2015, there were no amounts outstanding. In the first quarter of 2016, the Company entered into a services agreement with INC Research, LLC (“INC”), to provide pharmacovigilance services. Avista and certain of its affiliates are principal owners of both INC and the Company. The agreement has a term of three years. During the three and nine months ended September 30, 2016, the Company incurred costs associated with this agreement of approximately $0.3 million and $0.6 million, respectively. At September 30, 2016, $0.2 million was included in accrued expenses and other liabilities. The Company purchases inventory supplies from VWR Scientific (“VWR”). Avista and certain of its affiliates have ownership interests in each of VWR and the Company. During each of the three and nine months ended September 30, 2016 and 2015, the Company made purchases of $0.1 million and $0.2 million, respectively. At September 30, 2016 and December 31, 2015, $1,200 and $10,000, respectively, were included in accounts payable and accrued expenses.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Information	16. Segment Information The Company reports two operating segments, United States and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. All goodwill has been allocated to the United States operating segment. Selected information for each business segment are as follows: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Revenues United States $ 68,896 $ 64,420 $ 211,911 $ 194,897 International 10,443 14,911 34,816 44,003 Total revenues 79,339 79,331 246,727 238,900 Less: inter-segment revenue (6,276 ) (5,208 ) (19,224 ) (16,640 ) Total revenues, less inter-segment revenues $ 73,063 $ 74,123 $ 227,503 $ 222,260 Revenues from external customers United States $ 62,620 $ 59,212 $ 192,687 $ 178,257 International 10,443 14,911 34,816 44,003 Total revenues from external customers $ 73,063 $ 74,123 $ 227,503 $ 222,260 Operating income United States $ 14,135 $ 13,303 $ 43,469 $ 29,424 International (1,411 ) 2 1,281 587 Total operating income, including inter-segment 12,724 13,305 44,750 30,011 Inter-segment operating (loss) income (129 ) 103 (303 ) 131 Operating income 12,595 13,408 44,447 30,142 Interest expense, net (6,786 ) (7,100 ) (20,782 ) (31,599 ) Debt retirement costs (1,415 ) — (1,415 ) — Loss on extinguishment of debt — — — (15,528 ) Other (expense) income, net (154 ) (183 ) 300 234 Income (loss) before income taxes $ 4,240 $ 6,125 $ 22,550 $ (16,751 )

Business Overview (Policies)

Business Overview (Policies)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 2, 2016 and updated, as necessary, in this quarterly report. There were no other changes to the Company’s accounting policies since December 31, 2015. In the opinion of management, the accompanying unaudited condensed consolidated financial statements of Lantheus Holdings, Inc. include all normal and recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of September 30, 2016 and December 31, 2015, results of operations and comprehensive earnings for the three and nine months ended September 30, 2016 and 2015, and cash flows for the nine months ended September 30, 2016 and 2015. The results of operations for the nine months ended September 30, 2016 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Manufacturing and Customer Concentrations, Liquidity and Management’s Plans The Company currently relies on Jubilant HollisterStier (“JHS”) as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company recently completed its technology transfer activities at JHS and received Food and Drug Administration (“FDA”) approval for its Cardiolite product supply. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY. Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives. The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy. Borrowing capacity under the Company’s $50.0 million revolving credit facility (the “Revolving Facility”), is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves (the “Borrowing Base”). If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of September 30, 2016, the aggregate Borrowing Base was approximately $40.4 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $31.5 million. The Company’s senior secured term loan facility (the “Term Facility”), contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity. Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows (Topic 230) – Classification of Certain cash Receipts and Cash Payments In March 2016, the FASB, issued ASU 2016-09, Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842) Leases (Topic 840) In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606 Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis	The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, September 30, 2016 (in thousands) Total fair Quoted prices Significant other Significant Money market (1) $ 3,050 $ 3,050 $ — $ — Total $ 3,050 $ 3,050 $ — $ — December 31, 2015 (in thousands) Total fair Quoted prices Significant other Significant Money market (1) $ 1,586 $ 1,586 $ — $ — Certificates of deposit—restricted 74 — 74 — Total $ 1,660 $ 1,586 $ 74 $ — (1) Money market funds are included in cash and cash equivalents in the accompanying consolidated balance sheets; valued at quoted market prices in active markets.

Sales of Certain Internationa27

Sales of Certain International Segment Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Summary of Assets and Liabilities Sold and Held for Sale	The following table summarizes the major classes of assets and liabilities sold as of January 12, 2016 (date of the sale) and held for sale as of December 31, 2015: (in thousands) January 12, December 31, Current Assets: Accounts receivable, net $ 2,620 $ 2,512 Inventory 730 806 Other current assets 15 26 Total current assets 3,365 3,344 Non-Current Assets: Property, plant & equipment, net 760 791 Intangibles, net 462 480 Other long-term assets 28 29 Total assets held for sale $ 4,615 $ 4,644 Current Liabilities: Accounts payable $ 435 $ 430 Accrued expense and other liabilities 858 1,285 Total liabilities held for sale $ 1,293 $ 1,715

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Classified in Inventory or Other Long-Term Assets	Inventory was comprised of the following as of the end of each period: (in thousands) September 30, December 31, Raw materials $ 6,951 $ 7,506 Work in process 4,597 2,407 Finished goods 4,509 5,709 Total Inventory $ 16,057 $ 15,622

Property, Plant & Equipment, 29

Property, Plant & Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant & Equipment, Net	Property, plant & equipment consisted of the following: (in thousands) September 30, December 31, Land $ 14,950 $ 14,950 Buildings 70,294 68,941 Machinery, equipment and fixtures 66,229 60,787 Sub-total 151,473 144,678 Less: Accumulated depreciation (72,174 ) (67,260 ) Property, plant & equipment in service 79,299 77,418 Construction in progress 5,681 9,099 Property, plant & equipment, net $ 84,980 $ 86,517

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]
Schedule of Reconciliation of Company's Asset Retirement Obligations	The following is a reconciliation of the Company’s asset retirement obligations for the nine months ended September 30, 2016: (in thousands) Balance at December 31, 2015 $ 8,145 Net increase due to changes in estimated future cash flows 322 Accretion expense 698 Balance at September 30, 2016 9,165 Less: Amounts included in accrued expenses and other liabilities (455 ) Asset retirement obligation, long-term $ 8,710

Intangibles, net (Tables)

Intangibles, net (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangibles, Net	Intangibles, net consisted of the following: September 30, 2016 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ (8,298 ) $ 5,242 Straight-line Customer relationships 99,018 (89,115 ) 9,903 Accelerated Patents 42,780 (41,519 ) 1,261 Straight-line Total $ 155,338 $ (138,932 ) $ 16,406 December 31, 2015 (in thousands) Cost Accumulated Net Amortization Trademarks $ 13,540 $ (6,934 ) $ 6,606 Straight-line Customer relationships 100,737 (88,564 ) 12,173 Accelerated Patents 42,780 (41,063 ) 1,717 Straight-line Total $ 157,057 $ (136,561 ) $ 20,496
Schedule of Expected Future Amortization Expense Related to Intangible Assets	Expected future amortization expense related to the intangible assets is as follows: (in thousands) Remainder of 2016 $ 1,277 2017 3,341 2018 2,647 2019 1,804 2020 1,569 2021 and thereafter 5,768 $ 16,406

Accrued Expenses and Other Cu32

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other current liabilities are comprised of the following: (in thousands) September 30, December 31, Compensation and benefits $ 12,216 $ 10,525 Freight, distribution and operations 3,435 2,962 Accrued rebates, discounts and chargebacks 2,593 2,085 Accrued professional fees 1,636 1,493 Marketing expense 600 490 Research and development services 229 360 Other 1,141 587 Total accrued expenses and other current liabilities $ 21,850 $ 18,502

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Maturities of Principal Obligations Under Term Facility	The Company’s maturities of principal obligations under the Term Facility are as follows as of September 30, 2016: (in thousands) Remainder of 2016 $ 913 2017 3,650 2018 3,650 2019 3,650 2020 3,650 2021 and thereafter 289,925 Total debt 305,438 Less: Unamortized debt discount (3,139 ) Less: Unamortized debt issuance costs (4,067 ) Total 298,232 Less: Current portion of long-term debt (3,650 ) Total Long-term debt, net $ 294,582
Schedule of Term Facility Financial Covenants	The financial covenants are displayed in the table below: Term Facility Financial Covenants Period Total Net Leverage Ratio Q2 2016 to Q4 2016 6.00 to 1.00 Q1 2017 to Q2 2017 5.50 to 1.00 Thereafter 5.00 to 1.00

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense Recognized	The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Nine Months Ended (in thousands) 2016 2015 2016 2015 Cost of goods sold $ 120 $ 51 $ 259 $ 102 General and administrative 487 417 1,065 1,095 Sales and marketing 123 71 251 186 Research and development 147 52 294 141 Total stock-based compensation expense $ 877 $ 591 $ 1,869 $ 1,524

Net Income (Loss) Per Common 35

Net Income (Loss) Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Summary of Net Income (Loss) Per Common Share	During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted-average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. Three Months Ended Nine Months Ended (in thousands, except share and per share amounts) 2016 2015 2016 2015 Net income (loss) $ 4,220 $ 5,386 $ 21,893 $ (18,662 ) Basic weighted-average common shares outstanding 31,220,877 30,359,516 30,657,623 22,443,257 Effect of dilutive restricted stock awards 1,084,571 289,911 391,728 — Effect of dilutive stock options 96,849 112,344 — — Diluted weighted-average common shares outstanding 32,402,297 30,761,771 31,049,351 22,443,257 Basic income (loss) per weighted-average common share outstanding $ 0.14 $ 0.18 $ 0.71 $ (0.83 ) Diluted income (loss) per weighted-average common share outstanding $ 0.13 $ 0.18 $ 0.71 $ (0.83 )
Schedule of Stock Options and Nonvested Restricted Stock Excluded from Weighted Average Common Shares	The stock options and nonvested restricted stock excluded from weighted-average common shares because of their antidilutive effect for the three and nine months ended September 30, 2016 and 2015 include: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Stock Options 428,121 646,329 1,068,156 1,321,771 Restricted Stock 19,662 6,993 804,624 1,092,361

Other (Expense) Income, net (Ta

Other (Expense) Income, net (Tables)	9 Months Ended
	Sep. 30, 2016
Other Income and Expenses [Abstract]
Schedule of Other (Expense) Income, Net	Three Months Ended Nine Months Ended (in thousands) 2016 2015 2016 2015 Foreign currency losses $ (349 ) $ (628 ) $ (330 ) $ (989 ) Tax indemnification income 196 439 632 1,216 Other (expense) income (1 ) 6 (2 ) 7 Total Other (expense) income, net $ (154 ) $ (183 ) $ 300 $ 234

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Schedule of Selected Information for Each Business Segment	Selected information for each business segment are as follows: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Revenues United States $ 68,896 $ 64,420 $ 211,911 $ 194,897 International 10,443 14,911 34,816 44,003 Total revenues 79,339 79,331 246,727 238,900 Less: inter-segment revenue (6,276 ) (5,208 ) (19,224 ) (16,640 ) Total revenues, less inter-segment revenues $ 73,063 $ 74,123 $ 227,503 $ 222,260 Revenues from external customers United States $ 62,620 $ 59,212 $ 192,687 $ 178,257 International 10,443 14,911 34,816 44,003 Total revenues from external customers $ 73,063 $ 74,123 $ 227,503 $ 222,260 Operating income United States $ 14,135 $ 13,303 $ 43,469 $ 29,424 International (1,411 ) 2 1,281 587 Total operating income, including inter-segment 12,724 13,305 44,750 30,011 Inter-segment operating (loss) income (129 ) 103 (303 ) 131 Operating income 12,595 13,408 44,447 30,142 Interest expense, net (6,786 ) (7,100 ) (20,782 ) (31,599 ) Debt retirement costs (1,415 ) — (1,415 ) — Loss on extinguishment of debt — — — (15,528 ) Other (expense) income, net (154 ) (183 ) 300 234 Income (loss) before income taxes $ 4,240 $ 6,125 $ 22,550 $ (16,751 )

Business Overview - Additional

Business Overview - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016USD ($)Item
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of commercial products | Item	9
Revolving Line of Credit [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Maximum borrowing capacity	$ 50,000,000
Borrowing base	40,400,000
Unfunded standby letter of credit outstanding	8,800,000
Accrued interest	100,000
Available borrowing capacity	$ 31,500,000

Fair Value of Financial Instr39

Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 3,050	$ 1,660
Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value	3,050	1,586
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, restricted investments		74
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	3,050	1,586
Quoted Prices in Active Markets (Level 1) [Member] | Money Market [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value	$ 3,050	1,586
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		74
Significant Other Observable Inputs (Level 2) [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, restricted investments		$ 74

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Taxes And Tax Related [Line Items]
Provision for income taxes	$ 20	$ 739	$ 657	$ 1,911
Accounting Standards Update 2015-17 [Member]
Income Taxes And Tax Related [Line Items]
Noncurrent deferred tax assets					$ 100
Noncurrent deferred tax liabilities					$ 200

Sales of Certain Internationa41

Sales of Certain International Segment Assets - Additional Information (Detail) $ in Thousands, AUD in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016AUD
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Gain on sale of assets	$ 560	$ 6,505
Reclassification adjustment for gains on sales of assets included in net income (loss)	(435)	(435)
Canadian Radiopharmacies and Gludef Manufacturing and Distribution Business [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Purchase price for asset sale		9,000
Working capital adjustment		500
Gain on sale of assets		5,900
Australian Radiopharmacy Servicing Subsidiary [Member]
Assets Of Disposal Group Including Discontinued Operation [Line Items]
Gain on sale of assets	600	600
Sale price for share sale		1,500	AUD 2
Working capital adjustment in sale of stock units		1,500	2
Gross proceeds from sale of stock units		3,000	AUD 4
Net proceeds from sale of stock units		2,200
Working capital assets/liabilities sold	2,000	2,000
Reclassification adjustment for gains on sales of assets included in net income (loss)	$ 500	$ 500

Sales of Certain Internationa42

Sales of Certain International Segment Assets - Summary of Assets and Liabilities Sold and Held for Sale (Detail) - USD ($) $ in Thousands	Jan. 12, 2016	Dec. 31, 2015
Current Assets:
Total current assets		$ 4,644
Current Liabilities:
Total liabilities held for sale		1,715
Canadian Radiopharmacies and Gludef Manufacturing and Distribution Business [Member] | Disposal Group Held-for-sale Not Discontinued Operations [Member]
Current Assets:
Accounts receivable, net	$ 2,620	2,512
Inventory	730	806
Other current assets	15	26
Total current assets	3,365	3,344
Non-Current Assets:
Property, plant & equipment, net	760	791
Intangibles, net	462	480
Other long-term assets	28	29
Total assets held for sale	4,615	4,644
Current Liabilities:
Accounts payable	435	430
Accrued expense and other liabilities	858	1,285
Total liabilities held for sale	$ 1,293	$ 1,715

Inventory - Schedule of Invento

Inventory - Schedule of Inventory, Classified in Inventory or Other Long-Term Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 6,951	$ 7,506
Work in process	4,597	2,407
Finished goods	4,509	5,709
Total Inventory	$ 16,057	$ 15,622

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Non-current raw materials	$ 1.2	$ 1.2

Property, Plant & and Equipment

Property, Plant & and Equipment, Net - Schedule of Property, Plant & Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	$ 151,473	$ 144,678
Less: Accumulated depreciation	(72,174)	(67,260)
Property, plant & equipment in service	79,299	77,418
Property, plant & equipment, net	84,980	86,517
Land [Member]
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	14,950	14,950
Buildings [Member]
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	70,294	68,941
Machinery, Equipment and Fixtures [Member]
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	66,229	60,787
Construction in Progress [Member]
Property, Plant & Equipment [Abstract]
Property, plant & equipment, gross	$ 5,681	$ 9,099

Property, Plant & Equipment, 46

Property, Plant & Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Property, Plant & Equipment [Line Items]
Depreciation expense	$ 2,100	$ 1,900	$ 6,200	$ 9,600
Property, plant & equipment, net	84,980		84,980		$ 86,517
Fixed Assets Dedicated to R&D Activities [Member]
Property, Plant & Equipment [Line Items]
Property, plant & equipment, net	$ 3,900		$ 3,900

Asset Retirement Obligations -

Asset Retirement Obligations - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Financial assurance in form of surety bond	$ 28.2
Unfunded standby letter of credit	8.8
Asset retirement obligation liabilities expected, present value	$ 26.1

Asset Retirement Obligations 48

Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Asset Retirement Obligation Disclosure [Abstract]
Balance at the beginning of the period	$ 8,145
Net increase due to changes in estimated future cash flows	322
Accretion expense	698
Balance at the ending of the period	9,165
Less: Amounts included in accrued expenses and other liabilities	(455)
Asset retirement obligation, long-term	$ 8,710	$ 8,145

Intangibles, Net - Schedule of

Intangibles, Net - Schedule of Intangibles, Net (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Cost	$ 155,338	$ 157,057
Accumulated Amortization	(138,932)	(136,561)
Net	16,406	20,496
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated Amortization	(8,298)	(6,934)
Net	$ 5,242	6,606
Amortization Method	Straight-line
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 99,018	100,737
Accumulated Amortization	(89,115)	(88,564)
Net	$ 9,903	12,173
Amortization Method	Accelerated
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 42,780	42,780
Accumulated Amortization	(41,519)	(41,063)
Net	$ 1,261	$ 1,717
Amortization Method	Straight-line

Intangibles, Net - Additional I

Intangibles, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Amortization expense	$ 1.3	$ 1.5	$ 3.9	$ 4.5

Intangibles, Net - Schedule o51

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Intangible Liability Disclosure [Abstract]
Remainder of 2016	$ 1,277
2,017	3,341
2,018	2,647
2,019	1,804
2,020	1,569
2021 and thereafter	5,768
Net	$ 16,406	$ 20,496

Accrued Expenses and Other Cu52

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Compensation and benefits	$ 12,216	$ 10,525
Freight, distribution and operations	3,435	2,962
Accrued rebates, discounts and chargebacks	2,593	2,085
Accrued professional fees	1,636	1,493
Marketing expense	600	490
Research and development services	229	360
Other	1,141	587
Total accrued expenses and other current liabilities	$ 21,850	$ 18,502

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Debt retirement costs	$ 1,415,000	$ 1,415,000
Consolidated fixed charge coverage ratio to be maintained	100.00%	100.00%
Deposits to be made in case of default equaling, percentage of greatest amount of letter of credit drawn		105.00%
Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 365,000,000
Debt instrument discount percentage			1.25%
Debt instrument discount amount			$ 4,600,000
Increase in aggregate amount			37,500,000
Description of variable rate basis		The term loans under the Term Facility bear interest, with pricing based from time to time at the Company's election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%.
Interest rate at end of period	7.00%	7.00%
Prepayment terms		The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty.
Percentage of principal amount required to be paid quarterly		(0.25%)
Maturity date of term facility		Jun. 30, 2022
Percentage of net cash proceeds of all non-ordinary course sales or other dispositions of assets		100.00%
Percentage of net cash proceeds from issuances or incurrence of debt		100.00%
Percentage of excess cash flow		50.00%
Voluntary prepayment amount		$ 55,000,000
Debt retirement costs		1,400,000
Amount of cash in hand for voluntary prepayment of debt		15,100,000
Proceeds from follow on offering, net		$ 39,900,000
Seven Year Term Facility [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		5.00%
Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Increase in aggregate amount	$ 50,000,000	$ 50,000,000
Unfunded standby letter of credit outstanding	8,800,000	$ 8,800,000
Letter of credit, expiration date		Feb. 28, 2017
Renewal period of unfunded standby letter of credit		1 year
Period required for non renewal notification of debt instrument		60 days
Unfunded standby letter of credit payment term		The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017.
Borrowing base	40,400,000	$ 40,400,000
Available borrowing capacity	31,500,000	31,500,000
Accrued interest	100,000	100,000
Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Increase in aggregate amount	$ 50,000,000	$ 50,000,000
Description of variable rate basis		The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.
Unused line of credit fee (as a percent)		0.375%
Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400,000,000
Notes interest rate			9.75%
LIBOR [Member] | Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		6.00%
LIBOR [Member] | Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.00%
LIBOR [Member] | Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.00%
Reference Rate [Member] | Seven Year Term Facility [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.00%
Reference Rate [Member] | Revolving Line of Credit [Member] | LMI [Member]
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.00%

Financing Arrangements - Schedu

Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Less: Current portion of long-term debt	$ (3,650)	$ (3,650)
Total Long-term debt, net	294,582	$ 349,858
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Remainder of 2016	913
2,017	3,650
2,018	3,650
2,019	3,650
2,020	3,650
2021 and thereafter	289,925
Total debt	305,438
Less: Unamortized debt discount	(3,139)
Less: Unamortized debt issuance costs	(4,067)
Total	298,232
Total	298,232
Less: Current portion of long-term debt	(3,650)
Total Long-term debt, net	$ 294,582

Financing Arrangements - Sche55

Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail)	6 Months Ended	9 Months Ended	72 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2022
Senior Secured Term Loan Facility [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Total Net Leverage Ratio	5.50%	6.00%	5.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Apr. 26, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term	10 years
Time Based Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares that may be issued pursuant to awards		4,555,277

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 877	$ 591	$ 1,869	$ 1,524
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	120	51	259	102
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	487	417	1,065	1,095
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	123	71	251	186
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 147	$ 52	$ 294	$ 141

Net Income (Loss) Per Common 58

Net Income (Loss) Per Common Share - Summary of Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Net income (loss)	$ 4,220	$ 5,386	$ 21,893	$ (18,662)
Basic weighted-average common shares outstanding	31,220,877	30,359,516	30,657,623	22,443,257
Effect of dilutive restricted stock awards	1,084,571	289,911	391,728
Effect of dilutive stock options	96,849	112,344
Diluted weighted-average common shares outstanding	32,402,297	30,761,771	31,049,351	22,443,257
Basic income (loss) per weighted-average common share outstanding	$ 0.14	$ 0.18	$ 0.71	$ (0.83)
Diluted income (loss) per weighted-average common share outstanding	$ 0.13	$ 0.18	$ 0.71	$ (0.83)

Net Income (Loss) Per Common 59

Net Income (Loss) Per Common Share - Schedule of Stock Options and Nonvested Restricted Stock Excluded from Weighted Average Common Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	428,121	646,329	1,068,156	1,321,771
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	19,662	6,993	804,624	1,092,361

Other (Expense) Income, net - S

Other (Expense) Income, net - Schedule of Other (Expense) Income, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Other Income and Expenses [Abstract]
Foreign currency losses	$ (349)	$ (628)	$ (330)	$ (989)
Tax indemnification income	196	439	632	1,216
Other (expense) income	(1)	6	(2)	7
Total Other (expense) income, net	$ (154)	$ (183)	$ 300	$ 234

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jun. 25, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Avista [Member] | INC [Member]
Related Party Transaction [Line Items]
Costs incurred associated with agreement		$ 300,000		$ 600,000
Agreement term				3 years
Avista [Member] | INC [Member] | Accrued Expenses and Other Liabilities [Member]
Related Party Transaction [Line Items]
Purchases included in accrued expenses and other liabilities		200,000		$ 200,000
Avista [Member] | Advisory Services and Monitoring Agreement [Member]
Related Party Transaction [Line Items]
Annual fee				1,000,000
Costs incurred associated with agreement		0	$ 0	$ 0	$ 7,000,000
Agreement term				7 years
Aggregate termination fee paid	$ 6,500,000
Due from parent		0		$ 0		$ 0
VWR [Member]
Related Party Transaction [Line Items]
Purchases		100,000	$ 100,000	200,000	$ 200,000
VWR [Member] | Accounts Payable and Accrued Expenses [Member]
Related Party Transaction [Line Items]
Purchases included in accrued expenses and other liabilities		$ 1,200		$ 1,200		$ 10,000

Segment Information - Additiona

Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment Information - Schedule

Segment Information - Schedule of Selected Information for Each Business Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Revenues	$ 73,063	$ 74,123	$ 227,503	$ 222,260
Revenues	73,063	74,123	227,503	222,260
Operating income
Operating income	12,595	13,408	44,447	30,142
Interest expense, net	(6,786)	(7,100)	(20,782)	(31,599)
Debt retirement costs	(1,415)		(1,415)
Loss on extinguishment of debt				(15,528)
Other (expense) income, net	(154)	(183)	300	234
Income (loss) before income taxes	4,240	6,125	22,550	(16,751)
United States [Member]
Revenues
Revenues	62,620	59,212	192,687	178,257
Revenues	62,620	59,212	192,687	178,257
International [Member]
Revenues
Revenues	10,443	14,911	34,816	44,003
Revenues	10,443	14,911	34,816	44,003
Operating Segments [Member]
Revenues
Revenues	79,339	79,331	246,727	238,900
Revenues	79,339	79,331	246,727	238,900
Operating income
Operating income	12,724	13,305	44,750	30,011
Operating Segments [Member] | United States [Member]
Revenues
Revenues	68,896	64,420	211,911	194,897
Revenues	68,896	64,420	211,911	194,897
Operating income
Operating income	14,135	13,303	43,469	29,424
Operating Segments [Member] | International [Member]
Revenues
Revenues	10,443	14,911	34,816	44,003
Revenues	10,443	14,911	34,816	44,003
Operating income
Operating income	(1,411)	2	1,281	587
Inter-Segment [Member]
Revenues
Revenues	(6,276)	(5,208)	(19,224)	(16,640)
Revenues	(6,276)	(5,208)	(19,224)	(16,640)
Operating income
Operating income	$ (129)	$ 103	$ (303)	$ 131